Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.94% | 10.99% | -0.84% | -6.65% | -46.10% |
| Total Depreciation and Amortization | -15.73% | -29.94% | -34.64% | -25.63% | -2.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.42% | 126.23% | 1,386.98% | 59.73% | 548.39% |
| Change in Net Operating Assets | -174.78% | -146.98% | 5,000.00% | -268.53% | 86.64% |
| Cash from Operations | -26.16% | 7.39% | 9.54% | -57.59% | -32.16% |
| Capital Expenditure | -7,225.00% | -- | 100.19% | 98.04% | 99.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.86% | -999.98% | -158.10% | 2,790.62% | 143.61% |
| Cash from Investing | 23.87% | -999.98% | -159.16% | 3,236.83% | 142.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 63.74% | 74.78% | 65.59% | 50.41% | -11.02% |
| Issuance of Common Stock | -- | 8,000.00% | 363,153.13% | 1,734.44% | -100.00% |
| Repurchase of Common Stock | -268.63% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 79.46% | 9.21% | -- | -- | 17.24% |
| Cash from Financing | 683.67% | 75.60% | 65,561.86% | 1,078.95% | -14.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.69% | -131.19% | 1,216.58% | 28.51% | 96.30% |